Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) provides an update on operational activities and reports its consolid...
Total fourth quarter revenue of $878 million, an increase of 23% on a reported and core revenue basis, with Screening revenue of $695 million and Pre...
Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, announced financial results for the fourth quarte...
Belén Garijo to become Chief Executive Officer of Sanofi Sanofi's Board of Directors met on February 11, 2026, and decided not to renew the Direc...
Product Sales Excluding Veklury Increased 4% Year-Over-Year to $28.0 billion for Full Year 2025 Biktarvy Sales Increased 7% Year-Over-Year to $1...
Q4 2025: Net sales of $540 million (+4% at actual rates, +1% at constant exchange rates (CER)); diluted EPS of $0.49 and adjusted diluted EPS of $0.6...
In this BioPharma Boardroom interview, Jason Causon, Senior Technical Product Manager for Accurate Mass Platforms at SCIEX, explores how multiomi...
Drug delivery is entering a period of rapid reinvention, driven as much by analytical innovation as by molecular design. In this BioPharma BoardRoo...
As mRNA technologies move rapidly beyond COVID-19 into vaccines and therapies for cancer, rare diseases, and personalized medicine, scientific complexity i...
As regulators worldwide intensify scrutiny of per- and polyfluoroalkyl substances (PFAS), laboratories are being pushed into a new era of sensitivity, sp...
Dr. Albert Bourla, Chairman and CEO of Pfizer, said: “With excellent execution in 2025, we delivered a solid financial performance and strengt...
Preliminary results for 2025: Group sales revenue rises by 7.6 percent to around 3.5 billion euros Positive development in both divi...
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and ful...
Year-to-Date Revenue Declined by 2.8% at Constant Exchange Rate (CER), 3.3% atActual Exchange Rates (AER); Impact of VYVANSE® Generics is T...
© 2026 Biopharma Boardroom. All Rights Reserved.
